Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 99-102

  Bisagni, G ^a   Cocconi, G ^a   Scaglione, F ^b   Fraschini, F ^b   Pfister, Ch ^c   Trunet, P F ^c  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CIBA GEIGY LTD   (Switzerland)

Author keywords

Aromatase inhibitors; Breast carcinoma; Endocrine therapy; Letrozole

Indexed keywords

ALDOSTERONE; AROMATASE INHIBITOR; ESTRADIOL; HYDROCORTISONE; LETROZOLE;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030065503     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010490     Document Type: Article

References (12)

1. Bhatnagar AS, Haüsler A, Schieweck K et al. Highly selective inhibition of estrogen biosynthesis by CGS 20 267, a new non-steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 1990; 37: 1021-7.
2. Trunet PF, Mueller Ph, Bhatnagar AS et al. Open dose finding study of a new potent and selective non-steroidal aromatase inhibitor. CGS 20267. in healthy male subjects. J Clin Endocrinol Metab 1993; 77: 319-23.
3. Iveson TJ, Smith IE, Smithers DA et al. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20 267 in postmenopausal patients will advanced breast cancer. Cancer Res 1993; 53: 266-70.
4. Lipton A, Demers LM, Harvey HA et al. Letrozole (CGS 20 267). Phase I study of new potent oral aromatase inhibitor of breast cancer. Cancer 1995; 75: 2132-8.
5. Pfister CU, Duval M, Godbillon J et al. Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20 267 in biological fluids. J Pharm Sci 1994; 83: 520-4.
6. Trunet PF, Muller PH, Girard F et al. The effect of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 1992; 74: 571-6.
7. Brochu M, Fethiere J, Roy M et al. Highly sensitive and rapid radioimmunoassay for aldosterone in plasma and cell culture medium. Clin Biochem 1989; 22: 289-92.
8. Wilke TJ, Hirning DA. The evaluation of five commercial serum cortisol kits regarding precision and accuracy. Clin Biochem 1984; 17: 311-6.
9. Monfardini S, Brunner K, Crowther D et al. Evaluation of the cancer patients and the response to treatment. In Brunner K, Crowther D, Eckardt S et al. (eds): Manual of Adult and Paediatric Medical Oncology. Berlin: Springer-Verlag 1987; 22-38.
10. Cocconi G. First generation aromatase inhibitors: Aminoglutethimide and testololactone. Breast Cancer Res Treat 1994; 30: 57-80.
11. Brodie AMH, Santen RJ. Aromatase and its inhibitors in breast cancer treatment. Overview and perspective. Breast Cancer Res Treat 1994; 30: 1-6.
12. Iveson TJ, Smith IE, Smithers DA et al. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20 267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 324-31.